Pfizer entered into licensing agreements with two pharmaceutical companies based in India, strengthening its position in emerging markets and expanding its portfolio of medicines in its Established Products business unit.
Under the terms of an agreement with Aurobindo Pharma, Pfizer has acquired rights to 55 solid oral dose products and 5 sterile injectable products for patients in more than 70 emerging-market countries.
These medicines include antibiotics and anti-infectives, and cover a broad range of disease areas like cardiovascular and CNS disorders. Pfizer will commercialize 60 products in phases, tailoring its approach for different regions. Additionally, Pfizer expanded agreements with Aurobindo in developed markets, adding products in the U.S. and Europe.
Pfizer also entered into agreements with Claris Lifesciences to commercialize sterile injectable medicines after the products are no longer patent-protected and have lost market exclusivity in North America, Europe, Australia, and New Zealand.
Under the terms of the agreements, Pfizer has acquired rights to 15 injectable products covering a broad range of therapeutic areas including anti-infectives and pain.
To date, 128 non-Pfizer products—98 solid oral dose and 30 sterile injectables—have been added to Pfizer’s portfolio of established brands.
Pfizer Gains 39 Generic Therapies from Aurobindo (Mar. 3, 2009)